Key facts
- This page summarizes Patrick Lamy's Form 3 filing for Akero Therapeutics, Inc. (AKRO).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2023, 18:49.
Patrick Lamy - 10 Jan 2023 Form 3 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Exhibit 24: Power of Attorney Senior Vice President, Commercial Strategy
- Issuer ticker
- AKRO
- Reported as of
- 10 Jan 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 11 Jan 2023, 18:49:40 UTC
- Next SEC filing
- 12 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lamy filed Form 3 for Akero Therapeutics, Inc. (AKRO) on 11 Jan 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
Exhibit 24: Power of Attorney Senior Vice President, Commercial Strategy